ALUMIS INC. 8-K

What Happened Alumis Inc. announced on March 28, 2026 (via press release and a late-breaking oral presentation at the 2026 AAD Annual Meeting) that its oral drug envudeucitinib produced early and robust improvements in skin clearance, patient quality of life, and psoriasis symptoms in two Phase 3 trials for moderate-to-severe plaque psoriasis. The company said it plans to submit a New Drug Application (NDA) in the second half of 2026 and expects one‑year Phase 3 long‑term data to be available in the second half of 2026. The press release and presentation slides were attached to the 8-K as exhibits.

Key Details

• Event date: March 28, 2026 (press release and late‑breaker AAD presentation).
• Drug: envudeucitinib — showed early, robust improvements in skin clearance, quality of life, and psoriasis symptoms in two Phase 3 trials.
• Regulatory/near‑term milestones: Company plans NDA submission in H2 2026 and expects one‑year Phase 3 long‑term data in H2 2026.
• Development notes: Alumis referenced work on a once‑daily formulation, a pediatric development plan, the ongoing ONWARD program, and timing of a topline readout for the LUMUS Phase 2b program.

Why It Matters Positive Phase 3 data and a planned NDA submission are material near‑term clinical and regulatory milestones that could affect Alumis’ path to market and investor expectations. The company flagged specific upcoming catalysts (NDA filing and one‑year data in H2 2026), so investors should watch those timelines. The filing also contains forward‑looking statements and cautions that actual results, regulatory acceptance, and approval are subject to risks and uncertainties described in Alumis’ SEC filings.